Aurion Biotech Presses On with IPO Plans Amid Legal Dispute with Investor Alcon

Legal Dispute:
Aurion Biotech is facing a legal challenge from its investor Alcon, which has sued the company over its IPO plans, claiming violations of shareholder rights1 5.

IPO Progress:
Despite the legal pushback, Aurion Biotech is moving forward with its plans to go public, with a proposed listing on the NYSE under the symbol AURN3 4.

Company Background:
Aurion Biotech is a cell therapy startup that has received investment from Alcon, a major eye care company. The legal dispute has thrown the company's IPO plans into uncertainty1 2.

Current Status:
The exact IPO date is still unknown, but the company has filed for the IPO and is proceeding with its plans despite the ongoing legal battle3 4.

Investment Strategy:
The legal dispute highlights the challenges in early-stage investments, with companies like Takeda also tightening their reins on such investments and exploring option deals2.